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Abstract 
Objective: To estimate the association between the aggregation and pair‑wise combination of selected cardiovascu‑
lar risk factors (CVRF) and 10‑year all‑cause mortality.
Methods: Secondary data analysis of the PERU MIGRANT study, a prospective population‑based cohort. Ten‑year 
all‑cause mortality was determined for participants originally enrolled in the PERU MIGRANT Study (baseline in 2007) 
through the National Registry of Identification and Civil Status. The CVRF included hypertension, type 2 diabetes 
mellitus, hypercholesterolemia, and overweight/obesity. Exposures were composed of both the aggregation of the 
selected CVRF (one, two, and three or more CVRF) and pair‑wise combinations of CVRF. Cox regression models were 
used to calculate hazard ratios (HR) and 95% confidence intervals (95% CI).
Findings: Of the 989 participants evaluated at baseline, 976 (98.8%) had information about vital status at 10 years of 
follow‑up (9992.63 person‑years), and 63 deaths were recorded. In the multivariable model, adjusting for sociodemo‑
graphic and lifestyle variables, participants with two CVRF (HR: 2.48, 95% CI: 1.03–5.99), and those with three or more 
CVRF (HR: 3.93, 95% CI: 1.21–12.74) had higher all‑cause mortality risk, compared to those without any CVRF. The pair‑
wise combinations associated with the highest risk of all‑cause mortality, compared to those without such comor‑
bidities, were hypertension with type 2 diabetes (HR: 11.67, 95% CI: 3.67–37.10), and hypertension with overweight/
obesity (HR: 2.76, 95% CI: 1.18–6.71).
Conclusions: The aggregation of two or more CVRF and the combination of hypertension with type 2 diabetes or 
overweight/obesity were associated with an increased risk of 10‑year all‑cause mortality. These risk profiles will inform 
primary and secondary prevention strategies to delay mortality from cardiovascular risk factors.
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Introduction
Cardiovascular diseases represent the main cause of 
mortality worldwide. Of the total (17.7 million) estimated 
deaths worldwide from cardiovascular disease, more 
than three-quarters occurred in low- and middle-income 
countries (LMICs) [1]. These death rates are mainly 
driven by the presence of different cardiovascular risk 
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factors, including high blood pressure, type 2 diabetes 
mellitus, obesity, and hypercholesterolemia [2]. However, 
in many cases, these cardiovascular risk factors are not in 
isolation, but aggregated with other chronic conditions, 
in a way that increases the risk of disability, development 
of cardiovascular events, and mortality.
Multimorbidity, defined as the presence of two or more 
chronic conditions without any one disease taking prior-
ity over the other, is still more common in high-income 
countries (HICs). Previous research conducted in devel-
oped countries found that the risk of mortality is higher 
among individuals with more than two diseases com-
pared to disease-free individuals or those  with one dis-
ease [3, 4]. In low- and middle-income countries, the risk 
of mortality due to multimorbidity is rapidly increasing 
[3], including Peru, where the prevalence of cardiovascu-
lar risk factors are in the rise [6, 7]. Despite the burden of 
multimorbidity in LMICs, the characterization and long-
term consequences of having multiple chronic conditions 
remain largely unknown. As a result, medical care in 
LMICs often focuses on treating one disease rather than 
multiple diseases at once.
Current evidence evaluates the potential effect of mul-
timorbidity on disability and mortality, but do not deter-
mine which of the risk factors or chronic conditions are 
really associated with important outcomes. Evaluating 
which combination of conditions occurs more frequently 
and is associated with worse outcomes, such as mortality, 
should be particularly important in LMICs. Understand-
ing which higher-risk combinations should be target 
will help allocate resources more efficiently, especially 
in resource-constrained settings. Although some cohort 
studies have explored which are the most prevalent and 
lethal combinations of chronic conditions, one of them 
explored two to five diseases [8], whereas another one 
explored two and three conditions [9]. Moreover, the first 
study included individuals aged ≥ 65 years and the second 
study included a limited sample of individuals ≥ 85 years 
[9]. Thus, multimorbidity is not only a problem for the 
elderly and in order to intervene efficiently it is necessary 
to focus on the general population.
Cardiovascular risk factors are associated with life-
style and have changed rapidly in recent decades, some 
driven by urbanization [10]. Environmental changes 
and population flows have led to increased urbanization 
around the world, especially in low- and middle-income 
countries. The degree of urbanization is closely related 
to the distinctive characteristics of the health profile of 
rural and urban inhabitants, as well as of migrants from 
rural to urban areas, causing in the latter group a change 
in their lifestyle. The multimorbidity profile of these 
migrant groups is largely unknown and needs to be fur-
ther examined.
Therefore, in order to provide evidence on the long-
term effects of multimorbidity in LMICs, we aimed to 
estimate the 10-year all-cause mortality risk associated 
with the aggregation of selected cardiovascular risk fac-
tors. In addition, we also evaluated the strength and 
magnitude of the association between each pair-wise 




The PERU MIGRANT Study is a prospective population-
based cohort [4], that was established to assess the risk 
factors of cardiovascular disease in three population 
groups in Peru: urban dwellers, who were born and cur-
rently live in Pampas de San Juan de Miraflores, a periur-
ban area in Lima; rural inhabitants from San José de 
Secce and Chacas in Ayacucho (highlands settings); and 
rural-to-urban migrants, inhabitants born in Ayacucho 
(rural) who migrated to Pampas de San Juan de Miraflo-
res (urban).
Participants
Participants were recruited from 2007 to 2008 using a 
random sampling technique stratified by sex and age 
(30–39, 40–49, 50–59 and 60 + years) in each popula-
tion group using household census data [4]. For all study 
groups, men and women ≥ 30  years of age and habitual 
residents (≥ 6 months) of the study area were considered 
eligible. Pregnant women and people with mental disor-
ders that prevented them from giving informed consent 
were excluded.
Following a random selection process, participants 
were invited to participate. They provided consent to par-
ticipate in the study, completed a questionnaire, and had 
their anthropometric measurements assessed [4]. Sur-
vival data were retrieved through the National Registry 
of Identification and Civil Status (RENIEC) information 




All-cause mortality at 10  years of follow-up was the 
outcome of interest. After the RENIEC database was 
searched, participants were classified as alive or dead. 
Those participants who were not available in that data-
base (i.e. their national identity number was incorrectly 
recorded), were considered censored at the last time of 
contact (i.e. first or second in-person follow-up) [5, 6].
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Independent variables
Aggregation and pair-wise combinations of cardiovas-
cular risk factors were the independent variables. Risk 
factors included hypertension, type 2 diabetes mel-
litus, hypercholesterolemia, and overweight/obesity. 
These chronic cardiovascular risk factors were studied 
at baseline following standard procedures for all par-
ticipants [4]. Hypertension was defined as systolic blood 
pressure (SBP) ≥ 140  mm Hg, diastolic blood pressure 
(DBP) ≥ 90  mm Hg or self-reported diagnosis with the 
use of anti-hypertensive medications [7]. Type 2 dia-
betes mellitus was defined based on fasting blood glu-
cose ≥ 126  mg/dl or self-reported diagnosis with the 
use of anti-diabetic medications [8]. Overweight/obe-
sity was defined as a body mass index (BMI) ≥ 25 kg/m2 
[9]. Hypercholesterolemia was defined as total choles-
terol ≥ 200 mg/dl [10], and was assessed from blood sam-
ples drawn after an 8-h fasting period.
We examined mortality rates with different cardiovas-
cular risk profiles. In the first part, cardiovascular risk 
factors were aggregated and then split into one, two, and 
three or more cardiovascular risk factors. On the other 
hand, the second part comprised six groups of analy-
sis with selected cardiovascular risk factors (e.g., group 
1: hypertension with type 2 diabetes mellitus; group 
2: hypertension with hypercholesterolemia, etc.) Each 
group was evaluated in four categories: disease-free indi-
viduals (reference), people with only one disease (e.g., 
only hypertension and only type 2 diabetes mellitus), and 
the pair-wise combination (e.g., hypertension with type 
2 diabetes mellitus). The rationale of using this approach 
was to capture the individual effect of each chronic con-
dition in addition with the pair-wise combination using 
the same model, and in this way, avoiding misclassifica-
tion bias.
Covariables
Other variables were included in the analysis as potential 
confounders. Sociodemographic variables included age 
(30–39, 40–49, 50–59, and 60 + years), sex, migrant sta-
tus (rural, migrant or urban), education level (< 7 years of 
education vs. ≥ 7 years of education), and socioeconomic 
status (low, medium, or high), measured using a wealth 
index based on household income, assets and household 
facilities. Lifestyle variables included tobacco use (having 
smoked at least one cigarette per day compared to never 
users in the 6 months prior to the interview, and classi-
fied as yes or no), alcohol consumption (self-reported 
consumption of ≥ 6 beers or its equivalent in alcohol 
with other beverages on the same occasion at least once a 
month, and classified into low or high), HDL cholesterol 
(> HDL-c 40  mg/dl in men and > 50  mg/dl in women) 
[10], and high waist circumference (> 80  cm in women 
and > 90 cm in men) [11].
Statistical analysis
The statistical analysis was conducted in STATA 14 for 
Windows (STATA Corp, College Station, TX, USA). The 
characteristics of the study population were tabulated 
according to the population group at baseline, and Chi-
squared tests were used to compare categorical variables.
For the bivariate analysis, the log rank test was used 
to evaluate the association between sociodemographic 
variables, lifestyles, each cardiovascular risk factor, and 
aggregated cardiovascular risk factors and all-cause mor-
tality. The Cox proportional hazard model was used to 
estimate the effect of the aggregation of cardiovascular 
risk factors on all-cause mortality. Crude and adjusted 
models were computed. Adjusted models included soci-
odemographic and lifestyle variables.
The association between the pair-wise combinations 
of cardiovascular risk factors and all-cause mortality 
were evaluated separately using crude and adjusted Cox 
regression models. Adjusted models included sociode-
mographic and lifestyles variables, as well as the car-
diovascular risk factors not included in the pair-wise 
combination. Cox regression assumptions of independ-
ent observations, and independent censorship of survival 
and proportional risks were assessed. The latter assump-
tion was evaluated using the global test of Schoenfeld 
residuals. Given the number of confounding variables, 
the variance inflation factor was also utilized to evaluate 
the presence of collinearity.
Results
Characteristics of the study population
We analyzed the data of 989 participants included at 
baseline. Mean age was 47.9 years (SD: 12.0), and 52.8% 
of the cohort was female. Regarding population groups, 
201 (20.3%), 589 (59.6%), and 199 (20.1%) were rural, 
rural-to-urban migrants, and urban participants, respec-
tively (Table 1).
Prevalence of multimorbidity at baseline and 10‑year 
all‑cause mortality
At baseline, the prevalence of multimorbidity was 31.6% 
(95% CI: 28.7%–34.6%). Two cardiovascular risk factors 
were present in 25.0% (95% CI: 22.4%–27.8%) of the study 
population. Three or more risk factors were present in 
6.6% (95% CI: 5.3%–8.5%). These estimates were higher 
in the urban group than in the other two population 
groups (Table 1).
At 10-years of follow-up, the mortality incidence of 976 
(98.8%; 9992.6 person-years) participants was assessed. 
There were 63 deaths, resulting in an overall mortality 
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Table 1 Baseline characteristics of the PERU MIGRANT Study migrant status
The entries in parentheses refer to the corresponding percentages (%)
CVRF, Cardiovascular Risk Factors
*Chi‑squared test of homogeneity
Characteristics Rural N = 201 Migrant N = 589 Urban N = 199 p*
Sex 0.951
Female 106 (52.7) 309 (52.5) 107 (53.8)
Male 95 (47.3) 280 (47.5) 92 (46.2)
Age 0.574
30–39 years 61 (30.3) 164 (27.8) 57 (28.6)
40–49 years 56 (27.9) 173 (29.4) 53 (26.6)
50–59 years 46 (22.9) 167 (28.4) 59 (29.6)
60 + years 38 (18.9) 85 (14.4) 30 (15.1)
Education level < 0.001
< 7 years of education 162 (80.6) 282 (48.0) 36 (18.2)
> 7 years of education 39 (19.4) 306 (52.0) 162 (81.8)
Asset index < 0.001
Lowest 124 (61.7) 242 (41.1) 67 (33.7)
Middle 14 (7.0) 156 (26.5) 69 (34.7)
Highest 63 (31.3) 191 (32.4) 63 (31.7)
Current smoker < 0.001
No 190 (94.5) 530 (90.0) 159 (79.9)
Yes 11 (5.5) 59 (10.0) 40 (20.1)
Alcohol consumption 0.401
Low 178 (88.6) 542 (92.0) 182 (91.5)
High 23 (11.4) 47 (8.0) 17 (8.5)
Waist circumference < 0.001
Normal 168 (84.8) 233 (39.7) 66 (33.3)
High 30 (15.2) 354 (60.3) 132 (66.7)
HDL-c levels 0.735
Normal 113 (56.2) 341 (57.9) 108 (54.3)
High 88 (43.8) 248 (42.1) 91 (45.7)
Diabetes mellitus 0.002
No 197 (98.5) 568 (96.4) 183 (92.0)
Yes 3 (1.5) 21 (3.6) 16 (8.0)
Total cholesterol < 0.001
Normal 186 (92.5) 368 (62.6) 128 (64.3)
High 15 (7.5) 220 (37.4) 71 (35.7)
Hypertension < 0.001
No 177 (88.1) 518 (88.1) 144 (72.4)
Yes 24 (11.9) 70 (11.9) 55 (27.6)
Overweight/obesity < 0.001
Normal 160 (80.4) 189 (32.4) 56 (28.4)
Overweight/obesity 39 (19.6) 395 (67.6) 141 (71.6)
Aggregation of CVRF < 0.001
No CVRF 133 (67.2) 124 (21.3) 37 (18.8)
One CVRF 51 (25.8) 256 (43.9) 68 (34.5)
Two CVRF 14 (7.1) 165 (28.3) 64 (32.5)
Three or more CVRF 0 (0.0) 38 (6.5) 28 (14.2)
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rate of 6.3 (95% CI: 4.9–8.1) per 1,000 person-years, dis-
tributed as follows: 9.1 (95% CI: 5.7–14.4) in the rural 
group, 6.4 (95% CI: 3.7–11.1) in the urban group, and 5.3 
(95% CI: 3.8–7.5) in the rural to urban migrant group. 
Male sex, older age, low education level, low asset index, 
high waist circumference, type 2 diabetes, and hyperten-
sion were characteristics associated with higher all-cause 
mortality (Additional file 1: Table S1).
Aggregation and pair‑wise combinations of cardiovascular 
risk factors and 10‑year all‑cause mortality
The population characteristics according to vital status 
are shown in Additional file  1: Table  S1).  In the mul-
tivariate models adjusting for sociodemographic and 
lifestyle variables, participants with two cardiovascular 
risk factors had more than twice all-cause mortality risk 
compared to those without cardiovascular risk factors. 
Similarly, people with three or more cardiovascular risk 
factors had almost four times higher all-cause mortality 
risk than those without any cardiovascular risk factors 
(Table 2 & Additional file 1: Table S2).
When pair-wise combinations were assessed, subjects 
with hypertension and type 2 diabetes had a 12-fold 
increase in the risk of all-cause mortality compared to 
those without any of these conditions. In the same model, 
hypertension alone doubled such risk. On the other 
hand, subjects with hypertension and overweight/obesity 
together had almost three times the risk of all-cause mor-
tality, whereas hypertension alone increased such risk on 
3.2 times (Table 3 & Additional file 1: Table S3).
Discussion
In our study conducted in a low-resource LMIC set-
ting, we found that several aggregation or combination 
patterns of cardiovascular risk factors were strongly 
associated with an increased 10-year all-cause mortality 
risk. Of note, the combination of hypertension and type 
2 diabetes mellitus had a tenfold higher risk of mortality, 
whereas hypertension and overweight/obesity increased 
the 10-year all-cause mortality risk up to nearly four-fold. 
Additionally, having two or more cardiovascular risk fac-
tors was associated with a greater risk of mortality.
Previous studies have examined the risk of mortal-
ity among individuals with two or more chronic condi-
tions compared to those who were free of disease. Three 
independent conditions, i.e., diabetes mellitus, stroke, 
and myocardial infarction, have been associated with a 
similar increase in the risk of mortality, but their aggrega-
tion had a multiplicative effect on the risk of death [12]. 
Another recent study found that the risk of mortality 
associated with more than four chronic conditions was 
the same for each condition evaluated individually [13]. 
Our study, despite having evaluated a limited number of 
cardiovascular conditions, shows an additive effect for 
each additional cardiovascular risk factor as well as vary-
ing additive effects with different conditions. The effect of 
the aggregation of cardiovascular factors risk on mortal-
ity risk may be explained by the duration and severity of 
each additional risk factor [14].
We found that the co-occurrence of several pairs of 
diseases had a multiplicative effect on the all-cause mor-
tality risk. Hypertension-type 2 diabetes mellitus was 
associated with a twelve-fold higher all-cause mortal-
ity risk compared to a nearly three-fold risk in the case 
of hypertension and overweight/obesity. Our estimates 
were similar to those reported by other studies, in which 
cardiovascular mortality was elevated among individuals 
with type 2 diabetes mellitus and hypertension [15–17]. 
However, our findings differ with those reported by a 
meta-analysis, which demonstrated that high systolic 
blood pressure plus high serum cholesterol substantially 
increased cardiovascular mortality risk [18]. In this study, 
hypercholesterolemia, and its co-occurrence with type 
2 diabetes mellitus, overweight/obesity and hyperten-
sion had a minimal effect. Perhaps these comorbidities 
attenuated the proportional effects of hypercholester-
olemia on the risk of mortality. Our results also showed 
a non-significant association between overweight/obesity 
and type 2 diabetes mellitus and mortality risk. Addition-
ally, hypertension was associated with a higher mortality 
risk alone compared to when it co-occurred with cer-
tain cardiovascular risk factors (e.g., hypertension with 
overweight/obesity and hypertension with hypercholes-
terolemia). However, when hypertension was combined 
with type 2 diabetes mellitus, it resulted in a multipli-
cative mortality risk. The consistency of our findings 
has been reported in other studies [19, 20]. A possible 
explanation for this finding is that inadequate control of 
Table 2 Effect of the aggregation of cardiovascular risk factors 
and 10‑year mortality
HR, hazard ratio; IC, confidence interval; CVRF, Cardiovascular Risk Factors
*Adjusted by sociodemographic variables (age, sex, migrant status, level of 
education and asset index) and lifestyle variables (current smoker, alcohol 
consumption, HDL‑c levels, and waist circumference)
Variables Crude model Adjusted model*
HR (95% 
IC)
p‑value HR (95% IC) p‑value
Aggregation of CVRF
No CVRF Ref. Ref.
One CVRF 1.50 
(0.75–3.02)
0.252 2.04 (0.96–4.33) 0.064
Two CVRF 1.71 
(0.82–3.58)
0.155 2.48 (1.03–5.99) 0.043
Three or more CVRF 2.27 
(0.85–6.05)
0.101 3.93 (1.21–12.74) 0.023
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hypertension and diabetes increases the likelihood of life-
threatening complications and mortality. Therefore, the 
data presented highlights the need for primary preven-
tion of both hypertension and the combination of hyper-
tension with other cardiovascular risk factors.
The results of the prevalence of multiple conditions in 
LMICs vary. In this study, we evaluated the four most 
common chronic conditions in LMICs. Despite the lim-
ited number of chronic conditions chosen, the over-
all proportion of people with multimorbidity was high 
(25%), especially among urban dwellers. Our estimates of 
multimorbidity were similar to those reported in a study 
conducted in six LMICs [21], as well as others carried out 
in Scotland [22], and the Netherlands [23, 24]. However, 
the prevalence of multimorbidity was lower compared 
to a recent study that included nine HICs. In this study, 
the authors used 12 of the most prevalent chronic con-
ditions, and the data collection was performed between 
2007 and 2012. The highest frequency of multimorbid-
ity was observed in Russia (71.9%) and the lowest in 
China (45.1%) [25]. The variability in multimorbidity 
between studies can be attributed in part to the defini-
tion of multimorbidity used in each study, as there is a 
lack of consensus regarding it. The  Academy of Medi-
cal Sciences has suggested using “the presence of two or 
more chronic conditions without any one disease taking 
priority over the other” [3], and our analysis has applied 
that definition, but only for four conditions. Differences 
could also be due to  the number of conditions included 
in that definition; socioeconomic differences resulting in 
Table 3 Pair‑wise combinations of cardiovascular risk factors and 10‑year mortality
Variables Crude model Adjusted model
HR (IC 95%) HR (IC 95%)
Hypertension + Type 2 diabetes mellitus (n = 962) 
Normal Ref. Ref.
Hypertension 5.08 (3.01–8.58) 2.12 (1.17–3.85)
Type 2 Diabetes mellitus 1.92 (0.46–8.02) 1.30 (0.29–5.77)
Hypertension + Type 2 Diabetes mellitus 9.29 (3.28–26.27) 11.67 (3.67–37.10)
Hypertension + Hypercholesterolemia (n = 961)
Normal Ref. Ref.
Hypertension 6.88 (3.90–12.13) 2.51 (1.32–4.75)
Hypercholesterolemia 0.75 (0.34–1.67) 0.80 (0.34–1.87)
Hypertension + Hypercholesterolemia 2.46 (1.01–6.00) 2.00 (0.76–5.28)
Hypercholesterolemia + Type 2 Diabetes mellitus (n = 961)
Normal Ref. Ref.
Hypercholesterolemia 0.62 (0.32–1.16) 0.86 (0.42–1.77)
Type 2 Diabetes mellitus 3.41 (1.22–9.48) 3.38 (1.10–10.37)
Hypercholesterolemia + Type 2 Diabetes mellitus 1.47 (0.36–6.06) 1.61 (0.36–7.15)
Hypertension + Overweight/obesity (n = 964)
Normal Ref. Ref.
Hypertension 9.45 (4.67–19.11) 3.19 (1.48–6.86)
Overweight/obesity 0.89 (0.45–1.77) 1.12 (0.45–2.77)
Hypertension + Overweight/obesity 3.23 (1.54–6.80) 2.76 (1.18–6.71)
Overweight/obesity + Hypercholesterolemia (n = 962)
Normal Ref. Ref.
Overweight/obesity 0.91 (0.51–1.64) 1.37 (0.58–3.23)
Hypercholesterolemia 0.97 (0.37–2.56) 1.41 (0.49–4.04)
Overweight/obesity + Hypercholesterolemia 0.54 (0.25–1.16) 0.76 (0.26–2.25)
Overweight/obesity + Type 2 Diabetes mellitus (n = 961)
Normal Ref. Ref.
Overweight/obesity 0.74 (0.43–1.27) 1.17 (0.51–2.65)
Type 2 Diabetes mellitus 4.48 (1.06–18.87) 6.00 (1.33–27.11)
Overweight/obesity + Type 2 Diabetes mellitus 1.95 (0.68–5.58) 2.34 (0.66–8.36)
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lifestyle changes (e.g. improved transit that leads to less 
physical activity), sociodemographic differences between 
countries such as age and sex distribution, and the coun-
try’s phase of epidemiological and nutritional transition 
(e.g., greater exposure to fast foods) [25–28]. Due to 
this, it is necessary to conduct country-specific studies 
to better characterize and understand the epidemiology 
of multimorbidity. Currently, the provision of medical 
care in many LMIC settings is largely based on the treat-
ment of individual diseases. Additionally, although there 
are available guidelines for the treatment of people with 
multiple morbidities [29], it is necessary that these guide-
lines include care and treatment for people with LMIC-
specific multimorbidity [30].
One of the main strengths of this study is the 10-year 
follow-up in a LMIC setting and the use of a national 
records (RENIEC) database to obtain information about 
the number and date of deaths, thereby decreasing the 
differential classification bias. Additionally, participants 
were evaluated with standardized instruments and pro-
cedures. Also, lost to follow up rates were very low (i.e., 
1·2% of the total study population). Finally, we reduced 
misclassification bias by using four categories for each 
pair-wise combination instead of using only two (having 
or nor having the two conditions).
This study also has limitations. The limited number of 
deaths, despite the 10 years of follow-up, provides point 
estimates with wide confidence intervals. In addition, 
only four chronic cardiovascular conditions (hyperten-
sion, type 2 diabetes, hypercholesterolemia, and over-
weight/obesity) were evaluated at baseline, which limits a 
more detailed exploration of the potential effect of other 
conditions on mortality. Moreover, new cases of hyper-
tension, type 2 diabetes or hypercholesterolemia, or the 
variation of BMI over time was not considered. Besides, 
cardiovascular death should have been ideally the out-
come of interest. However, specific cause of death was 
not available. Finally, our biostatistical models only 
adjusted for main sociodemographic and lifestyle factors 
as confounding variables. We did not include other fac-
tors, such as race, in our baseline analysis.
Conclusion
After a 10-year follow-up period, we observed a higher 
risk of all-cause mortality when more cardiovascular risk 
factors were present. Additionally, the pair-wise combi-
nations of hypertension and type 2 diabetes mellitus and 
hypertension and overweight/obesity had the highest 
risks of death. These results suggest the need for better 
interventions targeted at people with multiple chronic 
conditions in LMIC settings.
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